{"id":56674,"date":"2026-02-09T21:11:05","date_gmt":"2026-02-09T13:11:05","guid":{"rendered":"https:\/\/flcube.com\/?p=56674"},"modified":"2026-02-09T21:11:07","modified_gmt":"2026-02-09T13:11:07","slug":"hengrui-pharmas-hrs-4642-wins-breakthrough-therapy-designation-for-kras-g12d-pancreatic-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56674","title":{"rendered":"Hengrui Pharma\u2019s HRS-4642 Wins Breakthrough Therapy Designation for KRAS G12D Pancreatic Cancer"},"content":{"rendered":"\n<p><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<strong><a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a><\/strong>) announced that <strong>HRS-4642<\/strong>, its <strong>KRAS G12D-targeting liposomal inhibitor<\/strong>, has been granted <strong>Breakthrough Therapy Designation (BTD)<\/strong> by China\u2019s <strong>Center for Drug Evaluation (CDE)<\/strong> for <strong>first-line treatment of advanced or metastatic pancreatic cancer with KRAS G12D mutation<\/strong>, in combination with <strong>gemcitabine and nab-paclitaxel<\/strong>. The designation recognizes HRS-4642 as the <strong>first-in-class KRAS G12D inhibitor<\/strong> globally to reach this regulatory milestone.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Jiangsu Hengrui Pharmaceuticals (SHA: 600276, HKG: 1276)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>CDE\/NMPA (China)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>HRS-4642 \u2013 KRAS G12D liposomal inhibitor<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Breakthrough Therapy Designation (BTD)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>First-line advanced\/metastatic pancreatic cancer (KRAS G12D mutation)<\/td><\/tr><tr><td><strong>Combination<\/strong><\/td><td>HRS-4642 + gemcitabine + nab-paclitaxel<\/td><\/tr><tr><td><strong>Global Status<\/strong><\/td><td>No approved KRAS G12D inhibitors domestically or internationally<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform-amp-mechanism-of-action\">Technology Platform &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drug Class:<\/strong> <strong>KRAS G12D-targeting small molecule inhibitor<\/strong> \u2013 Addresses the most common KRAS mutation in pancreatic cancer<\/li>\n\n\n\n<li><strong>Formulation:<\/strong> <strong>Liposomal delivery system<\/strong> \u2013 Enhances tumor penetration and reduces systemic toxicity<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong><\/li>\n\n\n\n<li><strong>Specifically binds KRAS G12D mutant protein<\/strong><\/li>\n\n\n\n<li><strong>Inhibits downstream MEK and ERK phosphorylation<\/strong><\/li>\n\n\n\n<li>Blocks oncogenic signaling driving tumor proliferation and survival<\/li>\n\n\n\n<li><strong>First-in-Class Status:<\/strong> No competing KRAS G12D inhibitors approved or in late-stage development globally<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-target-indication-amp-unmet-need\">Target Indication &amp; Unmet Need<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><th>Strategic Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Pancreatic Cancer Incidence<\/strong><\/td><td>~500,000 new cases annually in China; KRAS G12D in <strong>~40% of patients<\/strong><\/td><td>Large addressable population with mutation-specific targeting<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>Gemcitabine + nab-paclitaxel (median OS ~8-12 months)<\/td><td>Limited survival improvement over decades<\/td><\/tr><tr><td><strong>KRAS &#8220;Undruggable&#8221; History<\/strong><\/td><td>G12C inhibitors (sotorasib, adagrasib) recently approved; G12D remains elusive<\/td><td>HRS-4642 addresses larger mutation subset than G12C<\/td><\/tr><tr><td><strong>Combination Rationale<\/strong><\/td><td>Chemotherapy backbone + targeted inhibition<\/td><td>Potential for synergistic efficacy without overlapping toxicity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-market-context\">Strategic Positioning &amp; Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>KRAS G12D Market Opportunity:<\/strong> KRAS G12D represents the <strong>single most prevalent oncogenic driver<\/strong> in pancreatic ductal adenocarcinoma (PDAC), lung, and colorectal cancers\u2014collectively representing a <strong>multi-billion dollar unmet need<\/strong>.<\/li>\n\n\n\n<li><strong>Hengrui Innovation Pivot:<\/strong> BTD for HRS-4642 validates Hengrui\u2019s <strong>transition from generics to first-in-class oncology innovation<\/strong>, leveraging its <strong>liposomal formulation expertise<\/strong> and <strong>KRAS biology platform<\/strong>.<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> While <strong>Mirati (Bristol Myers Squibb)<\/strong>, <strong>Revolution Medicines<\/strong>, and <strong>Intellia<\/strong> pursue KRAS G12D programs, HRS-4642\u2019s <strong>BTD positions Hengrui as global leader<\/strong> with potential <strong>first-to-market advantage<\/strong> in the world&#8217;s second-largest pharmaceutical market.<\/li>\n\n\n\n<li><strong>Breakthrough Therapy Benefits:<\/strong> CDE BTD provides <strong>accelerated development and review pathways<\/strong>, enhanced regulatory dialogue, and potential <strong>conditional approval based on Phase II data<\/strong>\u2014compressing time-to-market by 12-18 months.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-roadmap\">Development Roadmap<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Activity<\/th><th>Anticipated Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>Current<\/strong><\/td><td>BTD granted; Phase I\/II trial ongoing<\/td><td>Q1 2026<\/td><\/tr><tr><td><strong>Near-term<\/strong><\/td><td>Phase II registrational data in first-line pancreatic cancer<\/td><td>2026-2027<\/td><\/tr><tr><td><strong>Expansion<\/strong><\/td><td>Monotherapy and combination studies in lung\/colorectal KRAS G12D<\/td><td>2026-2028<\/td><\/tr><tr><td><strong>Global Strategy<\/strong><\/td><td>US\/EU IND filing based on China efficacy data<\/td><td>2027<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding HRS-4642 clinical development in KRAS G12D-mutant cancers, regulatory timelines for BTD-enabled approval, and Hengrui Pharmaceuticals&#8217; global KRAS franchise expansion. Actual results may differ due to Phase II trial outcomes, competitive dynamics in the KRAS inhibitor space, and regulatory requirements for novel liposomal formulations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/600276_20260207_OBMR.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20260207_OBMR.\"><\/object><a id=\"wp-block-file--media-35bfe35c-a334-4357-83d7-57e30dcf44f4\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/600276_20260207_OBMR.pdf\">600276_20260207_OBMR<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/600276_20260207_OBMR.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-35bfe35c-a334-4357-83d7-57e30dcf44f4\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS-4642, its KRAS G12D-targeting&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[34,2586,4228,852],"class_list":["post-56674","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-breakthrough-therapy","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui Pharma\u2019s HRS-4642 Wins Breakthrough Therapy Designation for KRAS G12D Pancreatic Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS-4642, its KRAS G12D-targeting liposomal inhibitor, has been granted Breakthrough Therapy Designation (BTD) by China\u2019s Center for Drug Evaluation (CDE) for first-line treatment of advanced or metastatic pancreatic cancer with KRAS G12D mutation, in combination with gemcitabine and nab-paclitaxel. The designation recognizes HRS-4642 as the first-in-class KRAS G12D inhibitor globally to reach this regulatory milestone.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56674\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Pharma\u2019s HRS-4642 Wins Breakthrough Therapy Designation for KRAS G12D Pancreatic Cancer\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS-4642, its KRAS G12D-targeting liposomal inhibitor, has been granted Breakthrough Therapy Designation (BTD) by China\u2019s Center for Drug Evaluation (CDE) for first-line treatment of advanced or metastatic pancreatic cancer with KRAS G12D mutation, in combination with gemcitabine and nab-paclitaxel. The designation recognizes HRS-4642 as the first-in-class KRAS G12D inhibitor globally to reach this regulatory milestone.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56674\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-09T13:11:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-09T13:11:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56674#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56674\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Pharma\u2019s HRS-4642 Wins Breakthrough Therapy Designation for KRAS G12D Pancreatic Cancer\",\"datePublished\":\"2026-02-09T13:11:05+00:00\",\"dateModified\":\"2026-02-09T13:11:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56674\"},\"wordCount\":512,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Breakthrough therapy\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56674#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56674\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56674\",\"name\":\"Hengrui Pharma\u2019s HRS-4642 Wins Breakthrough Therapy Designation for KRAS G12D Pancreatic Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-09T13:11:05+00:00\",\"dateModified\":\"2026-02-09T13:11:07+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS-4642, its KRAS G12D-targeting liposomal inhibitor, has been granted Breakthrough Therapy Designation (BTD) by China\u2019s Center for Drug Evaluation (CDE) for first-line treatment of advanced or metastatic pancreatic cancer with KRAS G12D mutation, in combination with gemcitabine and nab-paclitaxel. The designation recognizes HRS-4642 as the first-in-class KRAS G12D inhibitor globally to reach this regulatory milestone.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56674#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56674\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56674#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Pharma\u2019s HRS-4642 Wins Breakthrough Therapy Designation for KRAS G12D Pancreatic Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Pharma\u2019s HRS-4642 Wins Breakthrough Therapy Designation for KRAS G12D Pancreatic Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS-4642, its KRAS G12D-targeting liposomal inhibitor, has been granted Breakthrough Therapy Designation (BTD) by China\u2019s Center for Drug Evaluation (CDE) for first-line treatment of advanced or metastatic pancreatic cancer with KRAS G12D mutation, in combination with gemcitabine and nab-paclitaxel. The designation recognizes HRS-4642 as the first-in-class KRAS G12D inhibitor globally to reach this regulatory milestone.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56674","og_locale":"en_US","og_type":"article","og_title":"Hengrui Pharma\u2019s HRS-4642 Wins Breakthrough Therapy Designation for KRAS G12D Pancreatic Cancer","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS-4642, its KRAS G12D-targeting liposomal inhibitor, has been granted Breakthrough Therapy Designation (BTD) by China\u2019s Center for Drug Evaluation (CDE) for first-line treatment of advanced or metastatic pancreatic cancer with KRAS G12D mutation, in combination with gemcitabine and nab-paclitaxel. The designation recognizes HRS-4642 as the first-in-class KRAS G12D inhibitor globally to reach this regulatory milestone.","og_url":"https:\/\/flcube.com\/?p=56674","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-09T13:11:05+00:00","article_modified_time":"2026-02-09T13:11:07+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56674#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56674"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Pharma\u2019s HRS-4642 Wins Breakthrough Therapy Designation for KRAS G12D Pancreatic Cancer","datePublished":"2026-02-09T13:11:05+00:00","dateModified":"2026-02-09T13:11:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56674"},"wordCount":512,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Breakthrough therapy","Hengrui Pharmaceuticals","HKG: 1276","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56674#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56674","url":"https:\/\/flcube.com\/?p=56674","name":"Hengrui Pharma\u2019s HRS-4642 Wins Breakthrough Therapy Designation for KRAS G12D Pancreatic Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-09T13:11:05+00:00","dateModified":"2026-02-09T13:11:07+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS-4642, its KRAS G12D-targeting liposomal inhibitor, has been granted Breakthrough Therapy Designation (BTD) by China\u2019s Center for Drug Evaluation (CDE) for first-line treatment of advanced or metastatic pancreatic cancer with KRAS G12D mutation, in combination with gemcitabine and nab-paclitaxel. The designation recognizes HRS-4642 as the first-in-class KRAS G12D inhibitor globally to reach this regulatory milestone.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56674#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56674"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56674#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Pharma\u2019s HRS-4642 Wins Breakthrough Therapy Designation for KRAS G12D Pancreatic Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56674"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56674\/revisions"}],"predecessor-version":[{"id":56677,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56674\/revisions\/56677"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56674"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56674"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}